CalciMedica (CALC) vs Chemomab Therapeutics (CMMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Chemomab Therapeutics (CMMB) has outperformed CalciMedica (CALC) over the past year, losing 53.0% versus a loss of 92.3%. Chemomab Therapeutics is the larger company by market cap ($9.6 million vs $8.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CALC | CMMB |
|---|---|---|
| Share price | $1.26 | $1.19 |
| Market cap | $8.69M | $9.58M |
| 1-day change | +7.69% | +4.39% |
| YTD return | -96.18% | -27.88% |
| 1-year return | -92.34% | -52.96% |
| 5-year return | — | -96.65% |
| EPS (TTM) | $-4.41 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-29.56M | $-8.99M |
| 52-week high | $36.00 | $2.99 |
| 52-week low | $1.00 | $0.92 |
| Distance from 52-week high | -96.50% | -60.20% |
| Analyst consensus | none | none |
| Avg. price target upside | +3868.25% | +320.17% |
| Average volume | 80.15K | 102.39K |
| Shares outstanding | 6.90M | 8.05M |
| Employees | 15 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CMMB has outperformed CALC by 39.4 percentage points over the past year.
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations
CALC vs CMMB FAQ
Which is bigger, CalciMedica or Chemomab Therapeutics?
Chemomab Therapeutics (CMMB) is larger, with a market capitalization of $9.58M compared with $8.69M for CalciMedica (CALC).
Which stock has performed better over the past year, CALC or CMMB?
CMMB returned -52.96% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.
Are CalciMedica and Chemomab Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.